Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1

Massano, 2012, Clinical approach to Parkinson's disease: features, diagnosis, and principles of management, Cold Spring Harb. Perspect. Med., 2, a008870, 10.1101/cshperspect.a008870 Postuma, 2015, MDS clinical diagnostic criteria for Parkinson's disease, Mov. Disord., 30, 1591, 10.1002/mds.26424 Dias, 2013, The role of oxidative stress in Parkinson's disease, J. Parkinsons Dis., 3, 461, 10.3233/JPD-130230 Pal, 2016, Role of neuroinflammation and latent transcription factors in pathogenesis of Parkinson's disease, Neurol. Res., 38, 1111, 10.1080/01616412.2016.1249997 Jackson-Lewis, 2012, Animal models of Parkinson's disease, Parkinsonism Relat. Disord., 18, S183, 10.1016/S1353-8020(11)70057-8 Langston, 2017, The MPTP story, J. Parkinsons Dis., 7, S11, 10.3233/JPD-179006 Blesa, 2015, Oxidative stress and Parkinson's disease, Front. Neuroanat., 9, 91, 10.3389/fnana.2015.00091 Dorszewska, 2014, Molecular effects of l-dopa therapy in Parkinson's disease, Curr. Genomics, 15, 11, 10.2174/1389202914666131210213042 Hinz, 2014, Parkinson's disease: carbidopa, nausea, and dyskinesia, Clin. Pharmacol., 6, 189 Athauda, 2016, The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action, Drug Discov. Today, 21, 802, 10.1016/j.drudis.2016.01.013 Maffei, 2015, Anti-incretin, anti-proliferative action of dopamine on β-cells, Mol. Endocrinol., 29, 542, 10.1210/me.2014-1273 Darsalia, 2013, The DPP-4 inhibitor Linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride, Diabetes, 62, 1289, 10.2337/db12-0988 Lin, 2016, The neuroprotective effects of the anti-diabetic drug linagliptin against Aβ-induced neurotoxicity, Neural Regen. Res., 11, 236, 10.4103/1673-5374.177724 Rauch, 2012, Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus, Diabetes Ther., 3, 10, 10.1007/s13300-012-0010-y Bentea, 2015, MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT, Neurosci. Lett., 593, 1, 10.1016/j.neulet.2015.03.013 Tammimäki, 2017, Delayed O-methylation of l-DOPA in MB-COMT-deficient mice after oral administration of l-DOPA and carbidopa, Xenobiotica, 1 Terawaki, 2014, Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury, Cardiovasc. Diabetol., 13, 154, 10.1186/s12933-014-0154-3 Nagai, 2016, Linagliptin ameliorates methyl glyoxal-induced peritoneal fibrosis in mice, PLoS One, 11, e0160993, 10.1371/journal.pone.0160993 Kabel, 2013, Effect of ubiquinone and resveratrol on experimentally induced parkinsonism, J. Res. Development, 1, 112 Haobam, 2005, Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains, Behav. Brain Res., 163, 159, 10.1016/j.bbr.2005.04.011 Sinha, 1972, Colorimetric assay of catalase, Anal. Biochem., 47, 389, 10.1016/0003-2697(72)90132-7 Marklund, 1974, Involvement of the superoxide anion radical in the autooxidation of pyrogallol and convenient assay for superoxide dismutase, Eur. J. Biochem., 47, 469e74, 10.1111/j.1432-1033.1974.tb03714.x Karuppagounder, 2013, Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats, Neuroscience, 236, 136, 10.1016/j.neuroscience.2013.01.032 Meteoglu, 2008, NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues, J. Exp. Clin. Cancer Res., 27, 53, 10.1186/1756-9966-27-53 Varghese, 2014, IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue sample, PLoS One, 9, e96801, 10.1371/journal.pone.0096801 Tanriover, 2010, The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease, Folia Histochem. Cytobiol., 48, 434, 10.2478/v10042-010-0047-6 Benjamini, 1995, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J. R. Stat. Soc. Ser. B, 57, 289 Manoharan, 2016, The role of reactive oxygen species in the pathogenesis of Alzheimer's disease, Parkinson's disease, and Huntington's disease: a mini review, Oxidative Med. Cell. Longev., 2016, 8590578, 10.1155/2016/8590578 Medeiros, 2016, Iron and oxidative stress in Parkinson's disease: an observational study of injury biomarkers, PLoS One, 11, e0146129, 10.1371/journal.pone.0146129 Colamartino, 2015, Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease, Neurotox. Res., 27, 106, 10.1007/s12640-014-9495-7 Blessing, 2003, Catechol-O-methyltransferase inhibition protects against 3, 4-dihydroxyphenylalanine (DOPA) toxicity in primary mesencephalic cultures: new insights into levodopa toxicity, Neurochem. Int., 42, 139, 10.1016/S0197-0186(02)00075-X Ahmadinejad, 2017, Molecular mechanisms behind free radical scavengers function against oxidative stress, Antioxidants, 6, 51, 10.3390/antiox6030051 Jami, 2014, Proteome analysis reveals roles of L-DOPA in response to oxidative stress in neurons, BMC Neurosci., 15, 93, 10.1186/1471-2202-15-93 Nakamura, 2016, Linagliptin has wide-ranging anti-inflammatory points of action in human umbilical vein endothelial cells, Jpn, Clin. Med., 7, 27 Johnson, 2015, Nrf2—a therapeutic target for the treatment of neurodegenerative diseases, Free Radic. Biol. Med., 88, 253, 10.1016/j.freeradbiomed.2015.07.147 Gui, 2016, X. Hu, NFE2L2 variations reduce antioxidant response in patients with Parkinson disease, Oncotarget, 7, 10756, 10.18632/oncotarget.7353 Todorovic, 2016, Nrf2: a modulator of Parkinson's disease?, J. Neural. Transm. (Vienna), 123, 611, 10.1007/s00702-016-1563-0 Abdelsalam, 2015, Neuroprotective effects of vidagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways, J. Neurochem., 133, 700, 10.1111/jnc.13087 Kabel, 2017, The promising effect of linagliptin and/or indole-3-carbinol on experimentally-induced polycystic ovarian syndrome, Chem. Biol. Interact., 273, 190, 10.1016/j.cbi.2017.06.009 Salcedo, 2012, Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders, Br. J. Pharmacol., 66, 1586, 10.1111/j.1476-5381.2012.01971.x Candeias, 2015, Gut-brain connection: the neuroprotective effects of the anti-diabetic drug liraglutide, World J. Diabetes, 6, 807, 10.4239/wjd.v6.i6.807 Ishibashi, 2011, Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level, Metabolism, 60, 1271, 10.1016/j.metabol.2011.01.010 Chao, 2014, Evidence of inflammatory system involvement in Parkinson's disease, Biomed. Res. Int., 2014, 308654, 10.1155/2014/308654 Sánchez-Capelo, 2003, Transforming growth factor beta1 overexpression in the nigrostriatal system increases the dopaminergic deficit of MPTP mice, Mol. Cell. Neurosci., 23, 614, 10.1016/S1044-7431(03)00081-2 Del-Bel, 2016, l-DOPA-induced dyskinesia in Parkinson's disease: are neuroinflammation and astrocytes key elements?, Synapse, 70, 479, 10.1002/syn.21941 Tiwari, 2017, The potential role of neuroinflammation and transcription factors in Parkinson disease, Dialogues Clin. Neurosci., 19, 71, 10.31887/DCNS.2017.19.1/rpal Shih, 2015, NF-kappaB signaling pathways in neurological inflammation: a mini review, Front. Mol. Neurosci., 8, 77, 10.3389/fnmol.2015.00077 Lee, 2016, Anti-inflammatory effects of GLP-1-based therapies beyond glucose control, Mediat. Inflamm., 2016, 3094642, 10.1155/2016/3094642 Bose, 2016, Mitochondrial dysfunction in Parkinson's disease, J. Neurochem., 139, 216, 10.1111/jnc.13731 Abuirmeileh, 2012, Exendin-4 treatment enhances l-dopa evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat, J. Pharm. Pharmacol., 64, 637, 10.1111/j.2042-7158.2011.01394.x